BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Cipla
Dow
Argus Health
Farmers Insurance
Mallinckrodt
Julphar
Daiichi Sankyo
Harvard Business School
Healthtrust

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,586,430

« Back to Dashboard

Summary for Patent: 6,586,430
Title: CCR5 modulators
Abstract:Compounds of Formula 1 which are useful as modulators of chemokine activity. The invention also provides pharmaceutical formulations and methods of treatment using these compounds.
Inventor(s): Armour; Duncan Robert (Kent, GB), Price; David Anthony (Kent, GB), Stammen; Blanda Luzia Christa (Kent, GB), Wood; Anthony (Kent, GB), Perros; Manoussos (Kent, GB), Edwards; Martin Paul (Kent, GB)
Assignee: Pfizer Inc. (New York, NY)
Application Number:09/452,578
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,586,430

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-003 Nov 4, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-004 Nov 4, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-001 Aug 6, 2007 RX Yes No ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-002 Aug 6, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,586,430

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9828420Dec 23, 1998
United Kingdom9921375Sep 10, 1999

Non-Orange Book US Patents Family Members for Patent 6,586,430

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,503,905 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives ➤ Subscribe
6,586,431 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives ➤ Subscribe
7,041,667 CCR5 modulators ➤ Subscribe
7,217,714 CCR5 modulators ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,586,430

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1697 ➤ Subscribe
Argentina 023345 ➤ Subscribe
Argentina 023363 ➤ Subscribe
Argentina 024233 ➤ Subscribe
Austria 266637 ➤ Subscribe
Austria 505190 ➤ Subscribe
Australia 1290400 ➤ Subscribe
Australia 1290500 ➤ Subscribe
Australia 1675100 ➤ Subscribe
Australia 760874 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Baxter
Moodys
Julphar
Daiichi Sankyo
Fish and Richardson
Express Scripts
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot